ArticleArchives of toxicology2026
Pharmacological correlates of topoisomerase II-directed protection against anthracycline-induced DNA damage and cardiotoxicity: a comparative evaluation of catalytic topoisomerase II inhibitors.
Article in Archives of toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Anthracyclines remain indispensable anticancer drugs, but their use is limited by dose-dependent cardiotoxicity involving topoisomerase IIβ (TOP2B)-mediated DNA damage in cardiomyocytes. To identify pharmacological features associated with TOP2-directed cardioprotection, we comparatively evaluated a chemically diverse panel of synthetic compounds, repurposed agents and natural products previously reported to modulate TOP2 activity, using dexrazoxane as the reference cardioprotectant. Recombinant human TOP2A and TOP2B inhibition was assessed by kDNA decatenation. Primary neonatal rat cardiomyocytes were pretreated with test compounds for 3 h and co-exposed to daunorubicin (DAU; 1.2 µM) for 3 h, followed by a 45-h drug-free period. TOP2 immunoreactivity was assessed after 24 h of compound exposure and DAU-induced γH2AX after 30-min pretreatment followed by 90-min DAU exposure. Effects on DAU antiproliferative activity were examined in HL-60 cells during 72-h exposure to 19 nM DAU. Dexrazoxane showed protective activity across the investigated endpoints. BNS-22 inhibited TOP2A and TOP2B with similar potency (IC₅₀ ≈ 2 µM for both isoforms) and produced the strongest protection among the experimental compounds, reducing DAU-induced LDH release by 55% at 10 µM, together with a 90% reduction in TOP2 immunoreactivity and 99.97% attenuation of DAU-induced γH2AX. BNS-22 did not attenuate DAU-induced antiproliferative activity in HL-60 cells. Resveratrol and suramin also provided significant protection at higher concentrations. Across this structurally diverse panel, biochemical TOP2 inhibition alone did not predict cardioprotection. Instead, protection was associated with a broader favourable cellular profile comprising low intrinsic toxicity, attenuation of anthracycline-induced DNA damage and, for the most effective compounds, reduced TOP2 immunoreactivity.
Indexed as
Identifiers
42919937What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.